6533b85efe1ef96bd12bff6c
RESEARCH PRODUCT
Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
Alessandro OlivieroGiuseppe VitaleFrancesco GiallauriaGiuseppe D'ambrosioAntonello D'andreaAlessandro ParlatoFilippo M. SarulloAnna Di LorenzoCinzia NugaraGabriella IannuzzoFrancesco PassaroFrancesco ClemenzaCrescenzo TestaMarco GentileRoberta CalceSilvia SarulloGiuseppe RomanoCarlo VigoritoMario PacileoElio Venturinisubject
medicine.medical_specialtyStress testingheart failurelcsh:Medicinecardiopulmonary exercise stress testing030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciencessacubitril/valsartan heart failure heart rate recovery peak oxygen consumption autonomic function cardiopulmonary exercise stress testing0302 clinical medicineInternal medicineHeart ratemedicine030212 general & internal medicinepeak oxygen consumptionheart rate recoveryEjection fractionbusiness.industrylcsh:RGeneral Medicinemedicine.diseaseValsartansacubitril/valsartanHeart failureBreathingCardiologyautonomic functionbusinesshuman activitiesSacubitril Valsartanmedicine.drugdescription
Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mortality in patients with cardiovascular disease. Sacubitril/valsartan (S/V) is a treatment for heart failure with reduced ejection fraction (HFrEF), which impressively impacts cardiovascular outcome. This study aims at evaluating the effects of S/V on HRR and its correlation with cardiopulmonary indexes in HFrEF patients. Methods: Patients with HFrEF admitted to outpatients&rsquo
year | journal | country | edition | language |
---|---|---|---|---|
2020-06-17 | Journal of Clinical Medicine |